Close Menu
Global News HQ
    What's Hot

    I Was Born Without Arms, but That Didn’t Stop Me From Becoming the World’s First Licensed Armless Pilot

    July 28, 2025

    Client Challenge

    July 28, 2025

    How leaders can be transparent about their belief systems without alienating anyone

    July 28, 2025
    Recent Posts
    • I Was Born Without Arms, but That Didn’t Stop Me From Becoming the World’s First Licensed Armless Pilot
    • Client Challenge
    • How leaders can be transparent about their belief systems without alienating anyone
    • Prince William and Princess Charlotte Share a Sweet Moment Cheering on England’s Lionesses to Euros Victory
    • Get AMD’s 7800X3D gaming CPU, plus a white Gigabyte B650E Aorus Elite motherboard for $449 at Newegg
    Facebook X (Twitter) Instagram YouTube TikTok
    Trending
    • I Was Born Without Arms, but That Didn’t Stop Me From Becoming the World’s First Licensed Armless Pilot
    • Client Challenge
    • How leaders can be transparent about their belief systems without alienating anyone
    • Prince William and Princess Charlotte Share a Sweet Moment Cheering on England’s Lionesses to Euros Victory
    • Get AMD’s 7800X3D gaming CPU, plus a white Gigabyte B650E Aorus Elite motherboard for $449 at Newegg
    • 5 Quick Decluttering Tasks Minimalists Do Every Morning to Maintain a Tidy Home
    • Year of the stablecoin: The GENIUS Act, Wall Street, and the dollar’s digital leap
    • Why Small Business Must Adopt AI
    Global News HQ
    • Technology & Gadgets
    • Travel & Tourism (Luxury)
    • Health & Wellness (Specialized)
    • Home Improvement & Remodeling
    • Luxury Goods & Services
    • Home
    • Finance & Investment
    • Insurance
    • Legal
    • Real Estate
    • More
      • Cryptocurrency & Blockchain
      • E-commerce & Retail
      • Business & Entrepreneurship
      • Automotive (Car Deals & Maintenance)
    Global News HQ
    Home - Finance & Investment - Why Summit Therapeutics Stock Soared 8% Higher Today | The Motley Fool
    Finance & Investment

    Why Summit Therapeutics Stock Soared 8% Higher Today | The Motley Fool

    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Why Summit Therapeutics Stock Soared 8% Higher Today | The Motley Fool
    Share
    Facebook Twitter LinkedIn Pinterest Email

    One day before the July Fourth holiday, the stock of clinical-stage biotech Summit Therapeutics (SMMT 8.18%) exploded like a powerful fireworks display. Shares of the cancer-focused company leaped by 8%, on a media report that a well-known peer was interested in a licensing deal. That rise bettered the S&P 500‘s (^GSPC 0.83%) 0.8% increase by several orders of magnitude.

    15 billion new reasons to consider the stock

    The media outlet in question was Bloomberg, which that morning published an article asserting that AstraZeneca is in talks with Summit about a partnership between the two companies.

    Image source: Getty Images.

    According to unnamed “people familiar with the matter,” the piece stated that such a partnership would center on the investigational lung cancer treatment ivonescimab. The drug, which Summit licenses from Chinese peer Akeso, has recently attracted much attention from the healthcare community and investors alike. This was due to its impressive performance in a late-stage clinical trial.

    Bloomberg’s sources said that the terms of a potential deal were still being hashed out. They might include an up-front payment of several billion dollars, and several milestone payments over time (this kind of structure is common in pharmaceutical industry licensing/partnership arrangements). All told, a deal between the two companies could pay out as much as $15 billion.

    Both Summit and AstraZeneca declined comment on the Bloomberg article.

    Fingers crossed

    When a drug development program attracts $15 billion worth of interest from a major industry player with deep pockets, it’s almost indisputably a win. If the Bloomberg report is accurate and a deal is indeed in the works (and is ultimately agreed upon), it would open a great, powerful, and quick road to success for Summit. It’s little wonder investors were so happy about the possibility.

    Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy.

    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleSome Drugs Can Make You Extra Vulnerable to Sun and Heat
    Next Article Hurry, Lowe’s Is Giving Away Free Ego Batteries for the 4th of July

    Related Posts

    Client Challenge

    July 28, 2025

    Trump Wants Cane Sugar Coke: Will Soda Fans Pay Higher Prices and Taxes?

    July 27, 2025

    Wall Street Week Ahead

    July 27, 2025

    3 Reasons the Bitcoin Surge Isn’t Over | The Motley Fool

    July 27, 2025
    Leave A Reply Cancel Reply

    ads
    Don't Miss
    Travel & Tourism (Luxury)
    9 Mins Read

    I Was Born Without Arms, but That Didn’t Stop Me From Becoming the World’s First Licensed Armless Pilot

    For Travel + Leisure’s column Traveling As, we’re talking to travelers about what it’s like…

    Client Challenge

    July 28, 2025

    How leaders can be transparent about their belief systems without alienating anyone

    July 28, 2025

    Prince William and Princess Charlotte Share a Sweet Moment Cheering on England’s Lionesses to Euros Victory

    July 28, 2025
    Top
    Travel & Tourism (Luxury)
    9 Mins Read

    I Was Born Without Arms, but That Didn’t Stop Me From Becoming the World’s First Licensed Armless Pilot

    For Travel + Leisure’s column Traveling As, we’re talking to travelers about what it’s like…

    Client Challenge

    July 28, 2025

    How leaders can be transparent about their belief systems without alienating anyone

    July 28, 2025
    Our Picks
    Travel & Tourism (Luxury)
    9 Mins Read

    I Was Born Without Arms, but That Didn’t Stop Me From Becoming the World’s First Licensed Armless Pilot

    For Travel + Leisure’s column Traveling As, we’re talking to travelers about what it’s like…

    Finance & Investment
    1 Min Read

    Client Challenge

    Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required…

    Pages
    • About Us
    • Contact Us
    • Disclaimer
    • Homepage
    • Privacy Policy
    Facebook X (Twitter) Instagram YouTube TikTok
    • Home
    © 2025 Global News HQ .

    Type above and press Enter to search. Press Esc to cancel.

    Go to mobile version